References
Busse WW, Calhoun WF, Sedgwick JD. Mechanism of airway inflammation in asthma. Am Rev Respir Dis 1993;147:S20–4.
Grimes D, Sturm RJ, Marinari LR, Carlson RP, Berkenkopf JW, Musser JH, et al. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Europ J Pharmacol 1993;236:217–28.
Heaslip RJ, Grimes D, Berkenkopf JW, Ilsemann BA, Sickels BD, Weichman BM. Anti-leukotriene effects of WY-50,295 tromethamine in isolated pulmonary tissues. Europ J Pharmacol 1993;234:247–54.
Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991;256:929–37.
Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993;119:1059–66.
Malo PE, Bell RL, Shaughnessy TK, Summers JB, Brooks DW, Carter GW. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulm Pharmacol 1994;7:73–9.
Carlson RP, Hartman DA, Tomchek LA, Walter TL, Lugay JR, Calhoun W, et al. Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 1993;266:1125–38.
Howell RE, Sickels BD, Woeppel SL, Jenkins LP, Rubin EB, Weichman BM. Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs. J Pharmacol Exp Ther 1994;268:353–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Howell, R.E., Jenkins, L.P., Hartman, D.A. et al. Pulmonary pharmacology of WAY-126299A: A dual-acting 5-lipoxygenase inhibitor and leukotriene D4 antagonist. Inflamm Res 44 (Suppl 2), S170–S171 (1995). https://doi.org/10.1007/BF01778316
Issue Date:
DOI: https://doi.org/10.1007/BF01778316